Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Livagen Dosage Protocol | PeptideDosages.com

Livagen (20 mg Vial) Dosage Protocol Livagen Dosage Chart Livagen is dosed at 500 mcg–2 mg daily via subcutaneous injection in educational protocols. A 20 mg vial reconstituted with bacteriostatic water yields about 6.67 mg/mL. This information is for research

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Livagen (20 mg Vial) Dosage Protocol

Livagen Dosage Chart

Livagen is dosed at 500 mcg–2 mg daily via subcutaneous injection in educational protocols. A 20 mg vial reconstituted with bacteriostatic water yields about 6.67 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.

Typical daily range: 0.5–2.0 mg once daily (gradual titration over 8–12 weeks).

Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 0.0667 mg (66.7 mcg) on a U-100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Livagen (Lys-Glu-Asp-Ala) is a synthetic tetrapeptide bioregulator studied for its effects on peptidase inhibition and epigenetic modulation in aging tissues[1][4]. Preclinical research demonstrates Livagen strongly inhibits enkephalin-degrading enzymes[1] and induces heterochromatin decondensation with gene reactivation in aged cells[4]. No standardized human dosing exists; this educational protocol presents a once-daily subcutaneous approach based on analogy with similar peptide bioregulators.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read Livagen Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Standard / Gradual Approach (3 mL = ~6.67 mg/mL)

Weeks 1–2

0.5 mg (500 mcg)

7.5 units (0.075 mL)

Weeks 3–4

1.0 mg (1000 mcg)

15 units (0.15 mL)

Weeks 5–6

1.5 mg (1500 mcg)

22.5 units (0.225 mL)

Weeks 7–12

2.0 mg (2000 mcg)

30 units (0.30 mL)

Frequency: Inject once daily subcutaneously. This schedule uses a 3.0 mL dilution to yield measurable volumes on standard insulin syringes. For ≤10-unit (≤0.10 mL) administrations (e.g., the initial 7.5-unit dose), consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

Peptide Vials (Livagen, 20 mg each):

8 weeks ≈ 4 vials

12 weeks ≈ 7 vials

16 weeks ≈ 10 vials

Insulin Syringes (U-100):

Per week: 7 syringes (1/day)

8 weeks: 56 syringes

12 weeks: 84 syringes

16 weeks: 112 syringes

Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.

8 weeks (4 vials): 12 mL → 2 × 10 mL bottles

12 weeks (7 vials): 21 mL → 3 × 10 mL bottles

16 weeks (10 vials): 30 mL → 3 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each day.

Per week: 14 swabs (2/day)

8 weeks: 112 swabs → recommend 2 × 100-count boxes

12 weeks: 168 swabs → recommend 2 × 100-count boxes

16 weeks: 224 swabs → recommend 3 × 100-count boxes

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01AHK-Cu — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 50 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 50 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. AHK-Cu is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
02Teduglutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Teduglutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
03Thymogen — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Thymogen is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
04Davunetide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Davunetide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
05Humanin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Humanin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
Research context

Read sources and limitations before applying a claim.

Study Design and Tracking

Define target area, measured amount, frequency, duration, and primary endpoint before the first observation. Use consistent lighting, camera position, facial expression, and time of day for images. Keep other skincare products and cosmetic procedures consistent or document each change. Record dispensing mass or volume so each application is reproducible. Track redness, itching, burning, swelling, dryness, eye exposure, pH drift, and product separation.

Source: peptidedosages.com ↗

Research Models and How Lipogenesis Is Actually Measured

Understanding how AOD-9604 has been studied clarifies both what the data can support and what a real antilipogenic investigation would require. The methodology falls into three tiers, and only the first touches lipogenesis directly. Ex vivo and in vitro fat-tissue work. The foundational studies examined lipolysis and lipogenesis in adipose tissue and isolated fat cells, measuring free-fatty-acid and glycerol release, fat oxidation, and — critically — the activity of lipogenic enzymes such as acetyl-CoA carboxylase.23 Enzyme-activity assays of this kind are the appropriate tool for an antilipogenic claim, and they are the source of the strongest evidence that a C-terminal domain peptide can suppress fat synthesis. A more complete modern program would add radiolabeled- or deuterium-tracer incorporation into fatty acids to quantify DNL flux, plus expression of ACC, FASN, SREBP-1c, and ChREBP under the peptide. Rodent models. The most methodologically informative animal work is the β3-AR knockout study, a clean genetic approach that isolated the receptor’s contribution by comparing knockout and wild-type mice under identical treatment.4 Obese Zucker rats and ob/ob mice provided body-weight, fat-mass, and substrate-oxidation readouts.15 These are genetically obese metabolic models, well suited to whole-body fat-balance questions but blunt instruments for isolating lipogenesis from lipolysis, since net fat change reflects both. Human trials. The clinical methodology was appropriate for an obesity drug — randomized, double-blind, placebo-controlled designs with weight and body-composition endpoints, plus dedicated safety and pharmacokinetic studies.610 A safety and tolerability study specifically characterized the peptide in humans.6 But none of these used lipogenesis endpoints. To answer this article’s question in humans would require a purpose-built study: stable-isotope measurement of de novo lipogenesis, adipose and hepatic lipogenic-gene expression, and controlled dosing — work that has never been done for AOD-9604. The methodological bottom line is that the antilipogenic evidence is strongest exactly where it is least generalizable (isolated rodent fat-tissue enzyme assays) and absent exactly where it would matter most (human DNL flux). Until that gap is filled, any statement that AOD-9604 “reduces lipogenesis in humans” is hypothesis, not finding. Terminology used across this literature — lipogenesis, lipolysis, DNL, ACC, FASN — is defined for reference in the site’s peptide and metabolism glossary.

Source: dosagepeptide.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

LL-37 (5mg Vial) Dosage Protocol

Human cathelicidin host-defense peptide — unapproved research compound; no validated systemic dosing.

Source: dosagepeptide.com ↗
Potential benefits

Potential Benefits & Side Effects

Observations from preclinical and early research literature. May support reductions in fat mass while preserving lean muscle in animal models[8][9]. Associated with elevated NAD+ levels and SIRT1 activation in preclinical studies[2][3]. Enhanced grip strength observed in aged mice when combined with exercise[10]. Generally well tolerated; occasional reports of mild headache, transient jitteriness, or injection-site reactions. Long-term human safety data not established; this compound remains investigational.

Source: peptidedosages.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →